ARIAD Pharma (ARIA): Cutting PT On Iclusig Pricing - Jefferies

October 26, 2016 8:19 AM EDT
Get Alerts ARIA Hot Sheet
Price: $23.75 +0.21%

Rating Summary:
    11 Buy, 13 Hold, 3 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ARIA Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Eun Yang, reiterated his Buy rating on shares of ARIAD Pharmaceuticals (NASDAQ: ARIA) but cut his price target to $11.00 from $13.00 on assumed Iclusig 30mg at price parity to 15mg/45mg dose reducing the company's revenue opportunity.

The analyst cut Iclusig revenue est's by ~23% in >2017. He stated "Iclusig's pricing scheme has been overly aggressive, there is a clear therapeutic value to Iclusig (saving CML pts lives). In addition, any pipeline success (AP32788, Iclusig in 2L CML, brigatinib in 1L ALK+ NSCLC), albeit new data not until ~2018, would potentially provide meaningful medium-/long-term upside to the price target".

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $9.34 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment